- Home
- HOFT vs CYBN Comparison
HOFT vs CYBN Comparison
Compare HOFT & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- CYBN
- Stock Information
- Founded
- HOFT 1924
- CYBN 2019
- Country
- HOFT United States
- CYBN Canada
- Employees
- HOFT N/A
- CYBN N/A
- Industry
- HOFT Home Furnishings
- CYBN Pharmaceuticals and Biotechnology
- Sector
- HOFT Consumer Discretionary
- CYBN Health Care
- Exchange
- HOFT Nasdaq
- CYBN Nasdaq
- Market Cap
- HOFT 164.3M
- CYBN 177.9M
- IPO Year
- HOFT 1999
- CYBN N/A
- Fundamental
- Price
- HOFT $13.50
- CYBN $9.62
- Analyst Decision
- HOFT
- CYBN Strong Buy
- Analyst Count
- HOFT 0
- CYBN 3
- Target Price
- HOFT N/A
- CYBN $138.00
- AVG Volume (30 Days)
- HOFT 54.1K
- CYBN 213.0K
- Earning Date
- HOFT 12-05-2024
- CYBN 02-12-2025
- Dividend Yield
- HOFT 6.82%
- CYBN N/A
- EPS Growth
- HOFT N/A
- CYBN N/A
- EPS
- HOFT N/A
- CYBN N/A
- Revenue
- HOFT $389,779,000.00
- CYBN N/A
- Revenue This Year
- HOFT N/A
- CYBN N/A
- Revenue Next Year
- HOFT $14.18
- CYBN N/A
- P/E Ratio
- HOFT N/A
- CYBN N/A
- Revenue Growth
- HOFT N/A
- CYBN N/A
- 52 Week Low
- HOFT $12.75
- CYBN $6.50
- 52 Week High
- HOFT $25.80
- CYBN $19.84
- Technical
- Relative Strength Index (RSI)
- HOFT 39.25
- CYBN 50.92
- Support Level
- HOFT $12.92
- CYBN $8.83
- Resistance Level
- HOFT $13.64
- CYBN $9.41
- Average True Range (ATR)
- HOFT 0.47
- CYBN 0.59
- MACD
- HOFT 0.13
- CYBN 0.02
- Stochastic Oscillator
- HOFT 50.68
- CYBN 52.65
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp designs, imports, manufactures and market residential household furniture, hospitality and contract furniture, lighting, accessories, and home décor for sale to wholesale and retail merchandisers located principally in North America.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.